EW vs DXCM — Key Metrics

Metric EW (EDWARDS LIFESCIENCES CORP) DXCM (DEXCOM INC)
Price105.2382.52
Market Cap60.51 Billion30.78 Billion
P/E (TTM)59.4531.86
P/B (Quarterly)5.26111.758
P/S (TTM)9.076.03
Net Profit Margin (TTM)15.319.4
Gross Margin (TTM)78.063.4
ROE (TTM)9.736.5
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

EDWARDS LIFESCIENCES CORP
vs
 
DEXCOM INC
 
EDWARDS LIFESCIENCES CORP
vs
 
DEXCOM INC
Performance Comparison
AI Model Recommendation
EW · EDWARDS LIFESCIENCES CORP
hmmm...
DXCM · DEXCOM INC

Outperform

13
UnderperformOutperform
Recommendation Summary

Stock EW is projected to underperform the market, stock DXCM is projected to outperform the market. Upfront Recommendation: DXCM.

Financial Metrics
Prices delayed ~15 min
EW Metrics DXCM
$105.23 Price $82.52
— Market Capitalization —
59.45 Price to Earnings Ratio 31.86
9.07 Price to Sales 6.03
42.49 Price to FCF Ratio 28.02
11.62 Price to Gross Profit 9.51
55.45 Price to R&D 50.61
8.35 Price to Current Assets 7.86

EW vs DXCM at a glance

Edwards Lifesciences Corp (EW) and Dexcom INC (DXCM) are both Medical Devices companies in the Healthcare sector. EW is the larger, at $60.5 billion in market value against $30.8 billion for DXCM, about 2.0 times the size.

On trailing-twelve-month figures, EW trades at 59.5 times trailing earnings and DXCM at 31.9; net profit margins are 15.3% and 19.4%.

The Upfront Investment model currently rates EW Underperform and DXCM Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.